Drug Search Results
More Filters [+]

Ipatasertib

Alternative Names: ipatasertib, gdc-0068
Latest Update: 2024-07-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Akt Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ipatasertib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Slovenia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 46

Highest Development Phases

Phase 3: Breast Cancer|Oncology Unspecified|Prostate Cancer|Triple Negative Breast Cancer

Phase 2: Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma|Gastrointestinal Cancer|Intestinal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Uterine Cancer

Phase 1: Fallopian Tube Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2022-003414-36

P3

Active, not recruiting

Unknown

2033-09-11

2020-001847-16

P2

Active, not recruiting

Oncology Solid Tumor Unspecified

2033-03-18

UmbrellaMAX

P3

Recruiting

Oncology Unspecified

2033-03-01

36%

UmbrellaMAX

P3

Recruiting

Oncology Unspecified

2033-03-01

36%

BX44273

P3

Recruiting

Oncology Unspecified

2033-03-01

Recent News Events